A selective inhibitor of SRPK1
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SRPIN340

Item No. 16284

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
CAS Number
218156-96-8
Synonyms
  • SRPK Inhibitor
Molecular Formula
C18H18F3N3O
Formula Weight
349.4
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMSO: 15 mg/mlEthanol: 25 mg/mlEthanol:PBS (pH 7.2) (1:4): 0.2 mg/ml
λmax
265 nm
SMILES
O=C(C1=CC=NC=C1)NC2=C(N3CCCCC3)C=CC(C(F)(F)F)=C2
InChi Code
InChI=1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)
InChi Key
DWFGGOFPIISJIT-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $95

    Add

    10 mg

    $169

    Add

    25 mg

    $369

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    SRPIN340 is an isonicotinamide compound that inhibits SRPK1 (Ki = 0.89 µM).1 It is about 10-fold less effective against SRPK2 and does not inhibit the related SRPKs, Clk1 and Clk4.1 SRPIN340 suppresses the propagation of Sindbis virus in Vero cells and the replication of hepatitis C virus in Huh7/Rep-Feo-2a cells.1,2 By blocking SRPK1-mediated phosphorylation of SRSF1, SRPIN340 modulates alternative splicing of VEGF, reducing neovascularization both in cells and in animals.3,4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fukuhara, T., Hosoya, T., Shimizu, S., et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. USA 103(30), 11329-11333 (2006).

    2. Karakama, Y., Sakamoto, N., Itsui, Y., et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob. Agents Chemother. 54(8), 3179-3186 (2010).

    3. Ghadimi, M.P., Lopez, G., Torres, K.E., et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 11(8), 1758-1769 (2012).

    4. Gammons, M.V.R., Dick, A.D., Harper, S.J., et al. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 54(8), 5797-5806 (2013).

    5. Dong, Z., Noda, K., Kanda, A., et al. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Mol. Vis. 19, 536-543 (2013).